Vatalanib Dihydrochloride

• CAT Number: I002633
• CAS Number: 212141-51-0
• Molecular Formula: C₂₀H₁₅ClN₄•2HCl
• Molecular Weight: 419.73
• Purity: ≥95%
• Synonyms: N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;dihydrochloride
• Target: VEGFR
• Solubility: DMSO:32mg/mL
• Storage: 3 years -20℃ powder
• IC50: 37 nM (VEGFR2/KDR) [1]
• InChI: InChI=1S/C20H15ClN4.2ClH/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14;;/h1-12H,13H2,(H,23,25);2*1H
• InChIKey: AZUQEHCMDUSRLH-UHFFFAOYSA-N
• SMILES: C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4.Cl.Cl

Vatalanib Dihydrochloride（Cat No.:I002633）is a potent inhibitor of vascular endothelial growth factor receptors (VEGFR), designed to block angiogenesis, the formation of new blood vessels that support tumor growth. By inhibiting VEGFR signaling, Vatalanib reduces the blood supply to tumors, thereby limiting their growth and metastasis. It has been studied as a potential therapeutic agent for treating various cancers, including colorectal and renal cell carcinoma. Vatalanib’s ability to target multiple tyrosine kinases involved in angiogenesis makes it a promising candidate for cancer therapy, often in combination with other treatments.

Reference

[1]. Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8), 2178-2189.
[2]. Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18(2), 589-596.